文献速递神经免疫

多发性硬化合并COVID-19患者的临床特征与结局

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2020-01-01

基于法国Covisep多中心回顾性队列登记,纳入2020年3月1日至5月21日347例确诊或高度疑似COVID-19的多发性硬化患者,评估疾病严重程度(7分序贯量表≥3分)并分析相关因素。结果显示21.0%患者严重程度评分≥3分,3.5%死于COVID-19;年龄、EDSS≥6和肥胖为独立危险因素,未发现疾病修饰治疗与COVID-19严重程度相关。

要点

  • 年龄、EDSS≥6和肥胖是多发性硬化患者COVID-19重症的独立危险因素
  • 未接受疾病修饰治疗者重症比例高于接受治疗者(46.0% vs 15.5%,P < .001)
  • 未发现疾病修饰治疗暴露与COVID-19严重程度相关

核心结论

  • 在多发性硬化患者中,年龄、EDSS和肥胖是重症COVID-19的独立危险因素
  • 未发现疾病修饰治疗暴露与COVID-19严重程度相关

研究设计与样本

  • Covisep登记为多中心、回顾性、观察性队列研究,在MS专家中心、综合医院及协作神经科医生中开展
  • 纳入2020年3月1日至5月21日确诊或高度疑似COVID-19的多发性硬化患者347例
  • 患者平均(SD)年龄44.6(12.8)岁,249例为女性,平均(SD)病程13.5(10.0)年

主要发现

  • 未接受疾病修饰治疗者重症比例46.0%,接受治疗者15.5%(P < .001)
  • 年龄每增加10岁OR为1.9(95%CI,1.4-2.5),EDSS≥6的OR为6.3(95%CI,2.8-14.4),肥胖OR为3.0(95%CI,1.0-8.7)
  • EDSS对重症结局变异解释度最高(R2,0.2),其次为年龄(R2,0.06)和肥胖(R2,0.01)

关键数值与推荐

  • COVID-19严重程度采用7分序贯量表评估,范围1分(未住院且活动无受限)至7分(死亡),以3分(住院且不需吸氧)为切点
  • EDSS评分范围0至10分,以3分和6分为切点
  • 主要结局为COVID-19严重程度评分≥3分

临床怎么用

  • 根据年龄、EDSS和肥胖等独立危险因素识别多发性硬化患者中的COVID-19重症高风险人群
  • 上述危险因素可为疫情期间多发性硬化患者临床管理的个体化策略提供依据

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. OBJECTIVE: To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. DESIGN, SETTING, AND PARTICIPANTS: The Covisep registry is a multicenter, retrospective, observational cohort study conducted in MS expert centers and general hospitals and with neurologists collaborating with MS expert centers and members of the Société Francophone de la Sclérose en Plaques. The study included patients with MS presenting with a confirmed or highly suspected diagnosis of COVID-19 between March 1, 2020, and May 21, 2020. EXPOSURES: COVID-19 diagnosed with a polymerase chain reaction test on a nasopharyngeal swab, thoracic computed tomography, or typical symptoms. MAIN OUTCOMES AND MEASURES: The main outcome was COVID-19 severity assessed on a 7-point ordinal scale (ranging from 1 [not hospitalized with no limitations on activities] to 7 [death]) with a cutoff at 3 (hospitalized and not requiring supplemental oxygen). We collected demographics, neurological history, Expanded Disability Severity Scale score (EDSS; ranging from 0 to 10, with cutoffs at 3 and 6), comorbidities, COVID-19 characteristics, and outcomes. Univariate and multivariate logistic regression models were used to estimate the association of collected variables with COVID-19 outcomes. RESULTS: A total of 347 patients (mean [SD] age, 44.6 [12.8] years, 249 women; mean [SD] disease duration, 13.5 [10.0] years) were analyzed. Seventy-three patients (21.0%) had a COVID-19 severity score of 3 or more, and 12 patients (3.5%) died of COVID-19. The median EDSS was 2.0 (range, 0-9.5), and 284 patients (81.8%) were receiving DMT. There was a higher proportion of patients with a COVID-19 severity score of 3 or more among patients with no DMT relative to patients receiving DMTs (46.0% vs 15.5%; P < .001). Multivariate logistic regression models determined that age (odds ratio per 10 years: 1.9 [95% CI, 1.4-2.5]), EDSS (OR for EDSS ≥6, 6.3 [95% CI. 2.8-14.4]), and obesity (OR, 3.0 [95% CI, 1.0-8.7]) were independent risk factors for a COVID-19 severity score of 3 or more (indicating hospitalization or higher severity). The EDSS was associated with the highest variability of COVID-19 severe outcome (R2, 0.2), followed by age (R2, 0.06) and obesity (R2, 0.01). CONCLUSIONS AND RELEVANCE: In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and COVID-19 severity. The identification of these risk factors should provide the rationale for an individual strategy regarding clinical management of patients with MS during the COVID-19 pandemic.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020. PMID: 32589189. doi:10.1001/jamaneurol.2020.2581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。